NCT05933044已完成不适用
A Retrospective Observational, Multi-Centre, Cohort Study to Understand Real-World Treatment Patterns and Clinical Outcomes of Adult Patients With Locally Advanced, Unresectable Non-Small Cell Lung Cancer (Stage III) in Canada
适应症
干预措施
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- AstraZeneca
- 入组人数
- 662
- 试验地点
- 5
- 主要终点
- Overall survival
研究概览
简要总结
In the RELEVANCE study, we will develop a scalable electronic medical report data capture platform to collect and analyse real-world data in the stage III NSCLC population in Canada across several Canadian cancer centres. Subsequent analyses will examine treatment patterns and clinical outcomes, including overall survival, for these patients, stratified by durvalumab regimen or non-durvalumab regimen during the time of the PACIFIC Patient Support Program.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 130 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female aged 18 years or older
- •Patients must have histologically or cytologically documented diagnosis of NSCLC with a locally advanced, or locally recurrent (stage III) disease between November 1, 2017 and December 31, 2019 at the centre (Note: durvalumab uptake rate requires a secondary index date, such as initiation of CRT before availability of durvalumab in May 2018)
排除标准
- •Patients treated with durvalumab in clinical studies prior to the start date
- •Clinical trial patients where treatments received are blinded in the patient medical records
研究组 & 干预措施
Durvalumab cohort
All stage III non-small cell lung cancer (NSCLC) patients who received durvalumab
干预措施: Durvalumab (Drug)
结局指标
主要结局
Overall survival
时间窗: November 1, 2017 to August 31, 2022
次要结局
- Proportion of PACIFIC regimen initiation and uptake in patients who received CRT(November 1, 2017 to August 31, 2022)
- Reasons for treatment discontinuation(November 1, 2017 to August 31, 2022)
- Time-to-treatment discontinuation(November 1, 2017 to August 31, 2022)
- Rate and type of resection(November 1, 2017 to August 31, 2022)
- Treatments received including rates of concurrent chemoradiotherapy (cCRT) and sequential chemoradiotherapy (sCRT) use in unresectable disease(November 1, 2017 to August 31, 2022)
- Time to durvalumab initiation following CRT(November 1, 2017 to August 31, 2022)
- Rate and type of adverse events of special interest in the durvalumab cohort(November 1, 2017 to August 31, 2022)
研究者
研究点 (5)
Loading locations...
相似试验
尚未招募
不适用
Construction of Multicenter Retrospective Registry Cohort Database for Gallbladder CancerBiliary Tract DiseasesGallbladder CancerGallbladder NeoplasmsNCT06276153RenJi Hospital5,000
招募中
不适用
International Big Data Centre in Emergency MedicineEmergency MedicineNCT05616416Guangdong Provincial People's Hospital500,000
已完成
不适用
Pediatric Femur Fracture RegistryFemoral Shaft FractureNCT03211546AO Innovation Translation Center322
进行中（未招募）
不适用
DIAGNOSIS, TREATMENT AND OUTCOME OF LUNG CANCER PATIENTSNon Small Cell Lung CancerSmall-cell Lung CancerNCT05254119Mahmut Gumus6,000
已完成
不适用
An Observational Study to Evaluate Patient-Reported Experiences of Living With Moderate-to-Severe Plaque PsoriasisModerate to Severe Plaque PsoriasisNCT01555606Janssen Biotech, Inc.108